Evidence map›Paper›PMID 31467400›Full record

ArticleScientific reports2019

ADAM15 mediates upregulation of Claudin-1 expression in breast cancer cells.

Jens Mattern, Christian S Roghi, Melanie Hurtz, Vera Knäuper, Dylan R Edwards, Zaruhi Poghosyan

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Claudins in Cancer: A Current and Future Therapeutic Target.International journal of molecular sciences · 2024
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Comparison of Fixation Methods for the Detection of Claudin 1 and E-Cadherin in Breast Cancer Cell Lines by Immunofluorescence.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2022
    Article
  17. Review
  18. Review
  19. Extracellular Matrix Biomarkers in Colorectal Cancer.International journal of molecular sciences · 2021
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Jens MatternDivision of Cancer and Genetics, School of Medicine, College of Biomedical and Life Sciences, Cardiff University Heath Park, Cardiff, CF14 4XN, UK.
Christian S RoghiSchool of Biological Sciences and Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, UK.
Melanie HurtzDivision of Cancer and Genetics, School of Medicine, College of Biomedical and Life Sciences, Cardiff University Heath Park, Cardiff, CF14 4XN, UK.
Vera KnäuperOral and Biomedical Sciences, School of Dentistry, College of Biomedical and Life Sciences, Cardiff University, Heath Park, Cardiff, CF14 4XY, UK.ORCID http://orcid.org/0000-0002-3965-9924
Dylan R EdwardsSchool of Biological Sciences and Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, UK. Dylan.edwards@uea.ac.uk.ORCID http://orcid.org/0000-0002-3292-2064
Zaruhi PoghosyanDivision of Cancer and Genetics, School of Medicine, College of Biomedical and Life Sciences, Cardiff University Heath Park, Cardiff, CF14 4XN, UK. z.poghosyan@cardiff.ac.uk.ORCID http://orcid.org/0000-0003-4966-7618
Cardiff University · GBUniversity of East Anglia · GBStädtische Kliniken Mönchengladbach · DE

Funding

Cancer Research UK C1430/A11853
6 · The paper itself

Abstract

A Disintegrin and Metalloproteinase-15 (ADAM15) is a transmembrane protein involved in protein ectodomain shedding, cell adhesion and signalling. We previously cloned and characterised alternatively spliced variants of ADAM15 that differ in their intracellular domains and demonstrated correlation of the expression of specific variants with breast cancer prognosis. In this study we have created isogenic cell panels (MDA-MB-231 and MCF-7) expressing five ADAM15 variants including wild-type and catalytically inactive forms. The expression of ADAM15 isoforms in MDA-MB-231 cells led to cell clustering to varying degree, without changes in EMT markers vimentin, slug and E-cadherin. Analysis of tight junction molecules revealed ADAM15 isoform specific, catalytic function dependent upregulation of Claudin-1. The expression of ADAM15A, and to a lesser degree of C and E isoforms led to an increase in Claudin-1 expression in MDA-MB-231 cells, while ADAM15B had no effect. In MCF-7 cells, ADAM15E was the principal variant inducing Claudin-1 expression. Sh-RNA mediated down-regulation of ADAM15 in ADAM15 over-expressing cells reduced Claudin-1 levels. Additionally, downregulation of endogenous ADAM15 expression in T47D cells by shRNA reduced endogenous Claudin-1 expression confirming a role for ADAM15 in regulating Claudin-1 expression. The PI3K/Akt/mTOR pathway was involved in regulating Claudin-1 expression downstream of ADAM15. Immunofluorescence analysis of MDA-MB-231 ADAM15A expressing cells showed Claudin-1 at cell-cell junctions, in the cytoplasm and nuclei. ADAM15 co-localised with Claudin-1 and ZO1 at cell-cell junctions. Immunoprecipitation analysis demonstrated complex formation between ADAM15 and ZO1/ZO2. These findings highlight the importance of ADAM15 Intra Cellular Domain-mediated interactions in regulating substrate selection and breast cancer cell phenotype.

Indexed as

ADAM ProteinsBreast NeoplasmsCadherinsCell Line, TumorClaudin-1FemaleGene Expression Regulation, NeoplasticHumansMembrane ProteinsProtein IsoformsSignal TransductionTranscriptional ActivationUp-RegulationADAM15 protein, humanADAM ProteinsCadherinsClaudin-1Membrane ProteinsProtein Isoforms

Identifiers

PMID31467400
PMCPMC6715704
OpenAlexW2970354978

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.